26 May 2013
Keywords: Prana Biotech, PBT434, Parkinson;s disease, Development milestone
Article | 30 August 2012
Australia’s Prana Biotechnology (ASX: PBT) ,says that its lead compound in development for Parkinson's disease, PBT434, had progressed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 August 2012
29 August 2012
24 May 2013
© 2013 thepharmaletter.com